Kallyope Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$159.1M
Industry:Biotech
Founded:2015
Lead Investor(s):Polaris Partners, Lux Capital
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

    0
  • Kallyope received $21.0M in venture funding in December 2018.
  • 0
  • Kallyope's total funding is $159.1M.

Employee Data

  • Kallyope has 56 Employees.
  • Kallyope grew their employee count by 27% last year.
  • Kallyope currently has 7 job openings.

What Is Kallyope?

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company integrates cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and products that improve human health. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria Center® for Life Science in New York City. We currently have many openings across Kallyope and are searching for great candidates to become part of a highly integrated team working on the cutting edge of science to identify new approaches to human health. Check out our available jobs on our website, www.kallyope.com/careers. Don't see a position that interests you Email us anyway at careers@kallyope.com. We want to know you better.

keywords:Biotechnology,Healthcare

56

Number of Employees

N/A

Revenue (est)

7

Current Jobs

27%

Employee Growth %

$159.1M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
North Central B...
N/A2496%
Axsome Therapeu...
$4.8M310%$104.7M
Progenics Pharm...
$16.3M12115%
TG Therapeutics
$0.2M9519%
Trudeau Institu...
$10.1M7312%
BioSpherix, Ltd...
$5.3M366%
Strong Hospital
N/A14614%
Tri-Institution...
$5.3M4018%
IDEX Health & S...
$10.5M691%
Elysium Health
$7M5011%$31.2M

Kallyope News

15-Mar-19 - Researchers Use Pfizer's Anti-Smoking Drug Chantix to Control Neurons

Other companies working in the field of chemogenetics include Kallyope, a spinout from Columbia University. Kallyope's work focuses on the

5-Dec-18 - Kallyope Inc. Announces $21 Million Expansion of Series B Financing

5, 2018 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the

5-Feb-19 - Lauring Leaves Takeda for Chief Medical Officer Post at Kallyope

Brett Lauring is now the chief medical officer of Kallyope. Lauring comes to the New York-based biotech from Takeda Pharmaceutical (NYSE:

Kallyope Funding

DateAmountRoundLead InvestorsReference
2015-12-14$44.0MAPolaris PartnersArticle
2018-02-23$66.0MBArticle
2018-12-06$21.0MBArticle

Kallyope Executive Hires

DateNameTitleReference
2016-10-28Ann WeberVP Drug DiscoveryArticle
2019-02-06Brett LauringChief Medical OfficerArticle